Mode
Text Size
Log in / Sign up
N/A N=40 Randomized Single-blind

Closed Loop Propofol Administration in Pediatric Cardiac Surgery

Pediatric Cardiac Surgery · Intraoperative Awareness · Automated Drug Delivery

Enrolled (actual)
40
Serious AEs
0.0%
Results posted
Aug 2013
Primary outcome: Primary: Percentage of Time Bispectral Index(BIS) Remains+/-10 of Target — 77.4; 75 percentage of time

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
IAADS (Other); Manual propofol administration (Other)
Age
Pediatric, Adult · 5+ yrs
Sex
All
Sponsor
Post Graduate Institute of Medical Education and Research, Chandigarh
Primary completion
Dec 2012

Outcome Measures

OutcomeResultp-value
PRIMARY
Percentage of Time Bispectral Index(BIS) Remains+/-10 of Target
77.4; 75
SECONDARY
Median Performance Error(MDPE)
6; -7
SECONDARY
Median Absolute Performance Error(MDAPE)
12; 13
SECONDARY
Wobble
9; 11
SECONDARY
Percentage of Time Heart Rate Remains Within 25% of Pre-op Baseline
83.3; 80.5
SECONDARY
Percentage of Time Mean Arterial Pressure Remains Within 25% of Pre-op Baseline
83.8; 72.8
SECONDARY
Intra-operative Awareness
0; 0
SECONDARY
Divergence
0.02; -0.097
SECONDARY
Global Score
30.09; 34.12
SECONDARY
Intraoperative Phenylephrine Used (Pre CPB)
5.79; 16.92

Summary

The purpose of the study is to evaluate and compare the feasibility, efficacy and safety of IAADS (Improved Anaesthetic Agent Delivery System) for propofol anaesthesia against manual control using bispectral index in paediatric patients undergoing open heart surgery under cardio-pulmonary bypass.

Eligibility Criteria

Inclusion Criteria

  • Children, aged 5-18 years and ASA (American Society of Anesthesiology) physical status 2-3, planned for elective open heart surgery under general anaesthesia.

Exclusion Criteria

  • Patients weighing more than ±30% of ideal body weight.
  • Patients having neurological/psychological disorders or on psychoactive medications.
  • Patients belonging to NYHA (New York Heart Association) class IV.
  • Patients with severe stenotic valvular lesions, eg, mitral or aortic stenosis.
  • Patients with known allergy to propofol or any of its constituents.
  • Patients having severe pulmonary arterial hypertension.
  • Patients with cyanotic congenital heart disease.
  • Patients requiring deep hypothermic circulatory arrest during surgery.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01600287). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search